




IFW

Patent Docket P2014R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Mary E. Gerritsen et al. Serial No.: 10/824,075 Filed: 14 April 2004 For: METHODS AND COMPOSITIONS FOR SELECTIVE MODULATION OF VASCULARIZATION	Group Art Unit: 1646 Examiner: Not Yet Assigned Confirmation No: 7011 CUSTOMER NO: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 8, 2004  Tom Marrs
---	---

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

(X) **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

0 **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in 37 CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

(If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.)

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003 (**1276 OG 55**). Nevertheless, applicants stand ready to provide copies at the request

of the Examiner.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s) (Required)
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: November 8, 2004

By: 

Paul Naik, Ph.D.

Reg. No. 49,075

Telephone No. (650) 225-5530



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P2014R1

Serial No.

10/824,075

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Gerritsen et al.

Filing Date

15 Apr 2004

Group

1646

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	5,547,856	20.08.96	Paul J. Godowski et al.			13.07.93
	* 2	6,099,841	08.08.00	Hillan et al.			


OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	3	Bussolino et al., "Hepatocyte Growth Factor is a Potent Angiogenic Factor Which Stimulates Endothelial Cell Motility and Growth" <u>Journal of Cell Biology</u> 119(3):629-641 (November 1992)
	4	Couffinhal et al., "Animal Model: Mouse Model of Angiogenesis" <u>American Journal of Pathology</u> 152(6):1667-1679 (1998)
	5	Ferrara, N., "Role of Vascular Endothelial Growth Factor in Physiologic and Pathologic Angiogenesis: Therapeutic Implications" <u>Seminars in Oncology</u> 29(6):Suppl. 16:10-14 (2002)
	6	Filvaroff et al., "Stanniocalcin 1 Alters Muscle and Bone Structure and Function in Transgenic Mice" <u>Endocrinology</u> 143(9):3681-3690 (2002)
	7	Folkman, J., "Role of Angiogenesis in Tumor Growth and Metastasis" <u>Seminars in Oncology</u> 29(6):Suppl.16:15-18 (2002)
	8	Freund, Y.R. and Blair, P.B., "Depression of Natural Killer Activity and Mitogen Responsiveness in Mice Treated with Pristane" <u>J. Immunol.</u> 129:2826-2830 (1982)
	9	Fujiwara et al., "Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers" <u>Int. J. Oncol.</u> 16:799-804 (2000)
	10	Gerritsen et al., "In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set" <u>Physiol. Genomics</u> 10(1):13-20 (2002)
	11	Hayashi et al., "Potential Role of Hepatocyte Growth Factor, a Novel Angiogenic Growth Factor, in Peripheral Arterial Disease" <u>Circulation</u> 100(19 Suppl):II-301 - II-308 (1999)
	12	Hongo, J.S. et al., "Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β_1 " <u>Hybridoma</u> 14:253-260 (1995)
	13	Ito et al., "Angiogenesis but not collateral growth associated with ischemia after femoral artery occlusion" <u>Am. J. Physiol.</u> 273(3 Pt 2):H1255-H1265 (1997)
	14	Jennische et al., "Expression of hepatocyte growth factor in growing and regenerating rat skeletal muscle" <u>Am J Physiol</u> 265(1 Pt 1):C122-C128 (1993)
	15	Kahn et al., "Gene Expression Profiling in an in Vitro Model of Angiogenesis" <u>American Journal of Pathology</u> 156(6):1887-1900 (2000)
	16	Kohler and Milstein., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity." <u>Nature</u> . 256:495-497 (August 7, 1975)
	17	Koide et al., "Preparation of a Monoclonal Antibody Specific for Human Stanniocalcin" <u>Biol. Pharm. Bull.</u> 21(12):1352-1355 (1998)
	18	Maulik et al., "Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition" <u>Cytokine & Growth Factor Reviews</u> 13:41-59 (2002)
	19	McCudden et al., "Characterization of Mammalian Stanniocalcin Receptors" <u>Journal of Biological Chemistry</u> 277:45249-45258 (2002)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P2014R1

Serial No.

10/824,075

Applicant

Gerritsen et al.

Filing Date

15 Apr 2004

Group

1646

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

20	Miyazawa et al., "Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor" <u>Biochem. & Biophys. Res. Comm.</u> 163(2):967-973 (September 15, 1989)
21	Morishita et al., "Hepatocyte Growth Factor as Cardiovascular Hormone: Role of HGF in the Pathogenesis of Cardiovascular Disease" <u>Endocrine Journal</u> 49:273-284 (2002)
22	Nakamura et al., "Molecular Cloning and Expression of Human Hepatocyte Growth Factor" <u>Nature</u> 342:440-443 (November 23, 1989)
23	Okajima et al., "Primary Structure of Rat Hepatocyte Growth Factor and Induction of Its mRNA During Liver Regeneration Following Hepatic Injury" <u>European Journal of Biochemistry</u> 193:375-381 (1990)
24	Paciga et al., "Ovarian Stanniocalcin Is Structurally Unique in Mammals and Its Production and Release Are Regulated through the Luteinizing Hormone Receptor" <u>Endocrinology</u> 143:3925-3934 (2002)
25	To et al., "The roles of hepatocyte growth factor/scatter factor and Met receptor in human cancers (Review)" <u>Oncol Rep</u> 5(5):1013-1024 (1998)
26	Schmidt et al., "Levels of Vascular Endothelial Growth Factor, Hepatocyte Growth Factor/Scatter Factor and Basic Fibroblast Growth Factor in Human Gliomas and Their Relation to Angiogenesis" <u>Int. J. Cancer</u> 84(1):10-18 (1999)
27	Scholz et al., "Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis)" <u>Virchows Arch</u> 436(3):257-70 (2000)
28	Seki et al., "Isolation and Expression of cDNA for Different Forms of Hepatocyte Growth Factor from Human Leukocyte" <u>Biochem. and Biophys. Res. Commun.</u> 172(1):321-327 (October 15, 1990)
29	Tashiro et al., "Deduced Primary Structure of Rat Hepatocyte Growth Factor and Expression of the mRNA in Rat Tissues" <u>Proc. Natl. Acad. Sci. USA</u> 87:3200-3204 (1990)
30	Varghese et al., "Overexpression of Human Stanniocalcin Affects Growth and Reproduction in Transgenic Mice" <u>Endocrinology</u> 143:868-876 (2002)
31	Wagner et al., "Human Stanniocalcin Inhibits Renal Phosphate Excretion in the Rat" <u>Journal of Bone and Mineral Research</u> 12(2):165-171 (1997)
32	Wagner et al., "Molecular cloning and cDNA sequence analysis of coho salmon stanniocalcin" <u>Molecular and Cellular Endocrinology</u> 90(1):7-15 (1992)
33	Wagner et al., "Purification, Characterization, and Bioassay of Teleocalcin, a Glycoprotein from Salmon Corpuscles of Stannius" <u>General and Comparative Endocrinology</u> 63:481-491 (1986)
34	Xin et al., "Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in Vivo" <u>Am. J. Pathol.</u> 158(3):1111-1120 (2001)
35	Zlot et al., "Stanniocalcin 1 Is an Autocrine Modulator of Endothelial Angiogenic Responses to Hepatocyte Growth Factor" <u>The Journal of Biological Chemistry</u> 278(48):47654-47659 (2003)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.